Your Account
close button

Use our patient tools for secure, convenient, 24/7 access. Learn more

OR

This facility is a member of


Connect with us:

Ovary / Peritoneum / Fallopian Tube Cancer

   

A Randomized Double-Blind Phase 3 Trial Comparing EC145 and Pegylated Liposomal Doxorubicin (PLD/DOXIL®/CAELYX®) in Combination versus PLD in Participants with Platinum-Resistant Ovarian Cancer [EC-VF-06 Endocyte]

Principal Investigator:
S. K. Sharma, M.D,
Adventist Hinsdale Hospital
(630) 856-6757
Contact: Peg Gregus, RN, MSN

Can Diet and Exercise Modulate Ovarian, Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival? [GOG 0225]

Principal Investigator:
S. K. Sharma, M.D,
Adventist Hinsdale Hospital
(630) 856-6757
Contact: Peg Gregus, RN, MSN

A GCIC Intergroup Multicenter Phase III Trial of Open-Label Carboplatin and Paclitaxel +/- NCI-Supplied Agent: Bevacizumab (NSC #704865, IND #7921) Compared with Oxaliplatin and Capecitabine +/- Bevacizumab as First-Line Chemotherapy in Patients with Mucinous Epithelial Ovarian or Fallopian Tube Cancer (MEOC) [GOG 0241]

Principal Investigator:
S. K. Sharma, M.D,
Adventist Hinsdale Hospital
(630) 856-6757
Contact: Peg Gregus, RN, MSN

Chemotherapy Toxicity in Elderly Women with Ovarian, Primary Peritoneal or Fallopian Tube Cancer [GOG 0273]

Principal Investigator:
S. K. Sharma, M.D,
Adventist Hinsdale Hospital
(630) 856-6757
Contact: Peg Gregus, RN, MSN

Advanced, Persistent or Recurrent Disease

A Randomized Phase II Study of NCI-Supplied Cabozantinib (NSC #761968, IND #116059) versus Weekly Paclitaxel (NSC #673089) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer [GOG 0186K]

Principal Investigator:
S. K. Sharma, M.D,
Adventist Hinsdale Hospital
(630) 856-6757
Contact: Peg Gregus, RN, MSN

A Randomized Phase III Trial of Maintenance Chemotherapy Comparing Twelve Monthly Cycles of Single Agent Paclitaxel or Xytotax (CT-2103) (IND #70177) versus No Treatment until Documented Relapse in Women with Advanced Ovarian or Primary Peritoneal Cancer who Achieve a Complete Clinical Response to Primary Platinum/Taxane Chemotherapy [GOG 0212]

Principal Investigator:
S. K. Sharma, M.D,
Adventist Hinsdale Hospital
(630) 856-6757
Contact: Peg Gregus, RN, MSN

A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel alone or in Combination with Bevacizumab ( NSC #704865, IND #7921) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Fallopian Tube and Peritoneal Primary Cancer. NCI-Supplied Agents: Bevacizumab [GOG 0213]

Principal Investigator:
S. K. Sharma, M.D,
Adventist Hinsdale Hospital
(630) 856-6757
Contact: Peg Gregus, RN, MSN

A Phase II Evaluation of SU11248 (Sunitinib Malate) (IND# 74019, NSC# 736511) in the Treatment of Persistent or Recurrent Clear Cell Ovarian Cancer [GOG 0254]

Principal Investigator:
S. K. Sharma, M.D,
Adventist Hinsdale Hospital
(630) 856-6757
Contact: Peg Gregus, RN, MSN

A Phase II Evaluation of Elesclomol Sodium and Weekly Paclitaxel in the Treatment of Recurrent or persistent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer ( Sponsor: GOG, IND #110077) [GOG 0260] Temporarily closed to accrual

Principal Investigator:
S. K. Sharma, M.D,
Adventist Hinsdale Hospital
(630) 856-6757
Contact: Peg Gregus, RN, MSN

Quality of Life and Care Needs in Patients with Persistent or Recurrent Platinum-Resistant Ovarian, Fallopian Tube and Peritoneal Cancer [GOG 0267]

Principal Investigator:
S. K. Sharma, M.D,
Adventist Hinsdale Hospital
(630) 856-6757
Contact: Peg Gregus, RN, MSN

A Phase II Evaluation of Temsirolimus (CCI-779) (NCI Supplied: NSC# 683864, IND# 61010) in Combination with Carboplatin and Paclitaxel followed by Temsirolimus (CCI-779) Consolidation as First-Line Therapy in the Treatment of Stage III-IV Clear-Cell Carcinoma of the Ovary [GOG 0268]

Principal Investigator:
S. K. Sharma, M.D,
Adventist Hinsdale Hospital
(630) 856-6757
Contact: Peg Gregus, RN, MSN

A Study of the Local and Systemic Effects of Intraperitoneal Chemotherapy in the Treatment of Previously-Untreated Invasive Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma [GOG 0271]

Principal Investigator:
S. K. Sharma, M.D,
Adventist Hinsdale Hospital
(630) 856-6757
Contact: Peg Gregus, RN, MSN

Pilot Study of Standard Therapy for Prevention of Nausea and Emesis Associated with First-Line Post-Operative Intraperitoneal Chemotherapy [GOG 0272]

Principal Investigator:
S. K. Sharma, M.D,
Adventist Hinsdale Hospital
(630) 856-6757
Contact: Peg Gregus, RN, MSN

A Randomized, Double-Blind, Placebo-Controlled Phase II Study of VTX-2337 in Combination with Pegylated Liposomal Doxorubicin PLD) in Patients with Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer [GOG 3003]

Principal Investigator:
S. K. Sharma, M.D,
Adventist Hinsdale Hospital
(630) 856-6757
Contact: Peg Gregus, RN, MSN

Ovarian Stromal Tumor

A Randomized Phase II Trial of Paclitaxel and Carboplatin vs.Bleomycin, Etoposide and Cisplatin for Newly-Diagnosed Advanced Stage and Recurrent Chemonaive Stage Sex Cord Stromal Tumors of the Ovary
[GOG 0264]

Principal Investigator:
S. K. Sharma, M.D,
Adventist Hinsdale Hospital
(630) 856-6757
Contact: Peg Gregus, RN, MSN


 

Share